In-Depth Review on Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects.

To access full report with TOC, please visit Pulmonary Fibrosis - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
- The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

AdAlta Pty Ltd. Advinus Therapeutics Ltd Aeolus Pharmaceuticals, Inc. Afferent Pharmaceuticals, Inc. Angion Biomedica Corp. Apellis Pharmaceuticals Inc Asahi Kasei Pharma Corp. aTyr Pharma, Inc. Biogen Inc Bioneer Corporation BiOrion Technologies B.V. Bristol-Myers Squibb Company Celgene Corporation Chrysalis Pharma SAS Clanotech AB Compugen Ltd. Cynata Therapeutics Limited Diffusion Pharmaceuticals Inc. Digna Biotech, S.L. Elsalys Biotech SAS F. Hoffmann-La Roche Ltd. FibroGen, Inc. FibroStatin SL Galapagos NV Galectin Therapeutics, Inc. GenKyoTex S.A. GlaxoSmithKline Plc Global Blood Therapeutics, Inc. GNI Group Ltd. HEC Pharm Co., Ltd. Histocell S.L. Hydra Biosciences, Inc. iBio, Inc. Immunomet Therapeutics, Inc. Inventiva Isarna Therapeutics GmbH Kadmon Corporation, LLC Kasiak Research Private Limited KineMed, Inc. Kolltan Pharmaceuticals, Inc. Kyorin Pharmaceutical Co., Ltd. Lpath, Inc. Lung Therapeutics, Inc miRagen Therapeutics, Inc. Moerae Matrix, Inc. MorphoSys AG NicOx S.A. Nitto Denko Corporation Novartis AG Nuevolution AB Pharmaxis Limited Pharmicell Co., Ltd. Pluristem Therapeutics Inc. Promedior, Inc. ProMetic Life Sciences Inc. Pulmatrix, Inc. RedHill Biopharma Ltd. Respira Therapeutics Inc Rhizen Pharmaceuticals S.A. Ribomic Inc. Saje Pharma, LLC Sanofi Sirnaomics, Inc. Sorrento Therapeutics, Inc. SPR Biosciences LLC Symic Biomedical, Inc. TaiwanJ Pharmaceuticals Co., Ltd. Terpenoid Therapeutics, Inc. Teva Pharmaceutical Industries Ltd. Therabron Therapeutics, Inc. Vault Pharma Inc. Vericel Corporation Vicore Pharma AB Yuhan Corporation

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###